You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 128 Next »

Information for Reviewers

Text in black is part of the template used to create this document and is not under review. Please review the blue text; this text represents the changes made to the template that are specific to this QRS instrument.

Title

Acute Physiology and Chronic Health Evaluation II Clinical Classification (APACHE II)

CDISC ReferenceClinical Classification Supplement to the Analysis Data Model Implementation Guide
QRS Short NameAPACHE II
ADQRS Permission StatusPublic Domain
TeamCDISC ADaM Questionnaires, Ratings, and Scales (QRS) Subteam
Supplement Version1.0 (or higher as appropriate when doing a supplement revision)
StatusDRAFT (or "REVISION DRAFT" or "FINAL", as appropriate). Status will not be considered "Final" until the supplement is ready to be sent for publication.
Date2024-02-20
NotesThis supplement is intended to be used with other CDISC user guides for specific therapeutic/disease areas and follows the CDISC Analysis Data Model Implementation Guide. Naming conventions follow ADaMIG v1.1 or higher.


Revision History

DateVersion
2024-02-201.0 Draft

© 2024 Clinical Data Interchange Standards Consortium, Inc. All rights reserved.

1     General Considerations

This section describes the implementation of the analysis dataset for QRS instruments as based on the Basic Data Structure (BDS) described in the Analysis Data Model Implementation Guide (ADaMIG). The ADaMIG can be found on the CDISC website at https://www.cdisc.org/standards/foundational/adam. The BDS was chosen as the model for analysis datasets of QRS instruments because it supports a wide variety of analyses, including summaries of total score by timepoint as well as change from baseline by timepoint. This data structure allows the ADaM variables PARAM and PARAMCD to come directly from Study Data Tabulation Model (SDTM) variables RS.RSTEST and RS.RSTESTCD, respectively, for individually captured items, thus ensuring traceability between SDTM and ADaM data. If other analyses are required that are not supported by the BDS, then consideration would be needed as to the appropriate structure. Analysis requirements always drive the design of the analysis datasets.

This ADaM supplement is based on the Acute Physiology and Chronic Health Evaluation II (APACHE II) Clinical Classification Supplement Version 2.0 to the SDTM Implementation Guide for Human Clinical Trials (SDTMIG). 

Note that source SDTM score values may not be suitable for analysis because the values may need to be imputed or transformed. In addition, recalculation of collected values may be needed per analysis rules. In these cases, the derivation of AVAL may not be a simple copying of RS.RSSTRESN. 

These specific analysis implementation details for the APACHE II are meant to be used in conjunction with ADaMIG. All completed questionnaires, ratings, and scales documentation can be found on the CDISC website at: https://www.cdisc.org/foundational/qrs.

1.1   Representations and Warranties, Limitations of Liability, and Disclaimers

This document is a supplement to the ADaMIG and is covered under Appendix C of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix C of the ADaMIG for a complete version of this material.

CDISC does not endorse any QRS instrument and does not specify how to conduct clinical assessments, protocols, or analyses. CDISC disclaims any liability for your use of this material.

1.2   Copyright Status

CDISC believes this instrument to be in the public domain, but you should perform your own assessment. CDISC has included the APACHE II in the CDISC library of QRS data standards supplementsThere may be many versions of this instrument in the public domain or copyrighted. CDISC has chosen to use the version attached to the QRS supplement to the SDTMIG, and the QRS supplement to the ADaMIG is based on the same version.

Note: CDISC Controlled Terminology is maintained by National Cancer Institute (NCI) Enterprise Vocabulary Services (EVS). The most recent versions of the SDTM and ADaM controlled terminologies should be accessed through the CDISC website (https://www.cdisc.org/standards/terminology).

1.3   Known Issues

The Acute Physiology and Chronic Health Evaluation (APACHE II) is a severity of disease measurement and mortality estimation tool for adult subjects applied within 24 hours of admission to an intensive care unit (ICU). The instrument's intended use is for newly admitted subjects to the ICU. The instrument consists of individual items that are summed to create a total score. This instrument is generally collected once at Screening/Baseline. The total score is normally collected as part of the instrument with no instructions provided for handling missing data. In the majority of cases, where APACHE II is only assessed once and the collected total score used as a baseline covariate, the SDTM RS domain may be sufficient to support the analysis requirements, with a variable in ADSL copied directly from a result/value in SDTM. ADQRS-325 - Getting issue details... STATUS

The APACHE II total score is designed as a mortality prediction tool. It is not intended to influence the medical management or care of subjects during their ICU stay or to be calculated sequentially to show improvement or effect of interventions. The worst values recorded during the initial 24 hours in the ICU are recommended to be used in calculation of the total score but the measurements initially recorded during the subject’s admission can be used for practical reasons. 

Although the APACHE II total score is the most widely used ICU mortality prediction score, it has a number of limitations and shortcomings. The total score is not intended to be applied to specific populations such as liver failure or HIV subjects and is not accurate when dealing with subjects transferred from another unit or another hospital. This is known as lead time bias and is addressed in  APACHE III. ADQRS-326 - Getting issue details... STATUS The APACHE II total score must be recalibrated before it can be used in a population other than the general ICU population ADQRS-327 - Getting issue details... STATUS . ICU prediction scores in general need to be periodically recalibrated to reflect changes and improvements in practice and subject demographics. Be sure to discuss the use of this instrument with the appropriate regulatory authorities.

2     Rules and References

The primary source used in the development of this supplement is Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985; 13(10):818–29. 

All links are valid and referenced information is current as of the date of this ADaMIG QRS supplement. This supplement does not make recommendations for the handling of missing data or adoption of imputation methods.

3     Scoring Software

There is no known publicly available scoring software as of the date of this ADaMIG QRS supplement.

4     Introduction to the Instrument   

The APACHE II is a severity-of-disease classification system that uses a point score based on the initial values of 12 routine physiologic measurements, age, and previous health status. Scores range from 0 to 71 and higher scores correspond to more severe disease and a higher risk of death. The composite score is based on findings represented in other SDTM domains such as Laboratory Test Results (LB) and Vital Signs (VS).

5     Key Data Checks

The computed total score consists of integer values ranging from 0 to 71. The classification system consists of 11 physiology measures based on a numeric rating scale 0 to 4 where 0 reflects values within the normal range and an increase in the numeric rating scale represents an increase in the abnormality of the physiology measure in either the high or low direction. For Serum Creatinine, the measure is assessed on the same scale but double points are assigned for subjects with acute renal failure. The measure evaluating extent of impaired consciousness is calculated as 15 minus the Glasgow Coma Scale (GCS) Score, so that lower scores indicate mild or no impairment and higher scores represent more severe impairment (possible head and/or central nervous system injury) and range from 0 to 12. Chronological age is divided into age groups which are assigned values of 0, 2, 3, 5, or 6. For subjects with a history of severe organ system insufficiency or who are immunocompromised, a numeric rating of 2 or 5 is assigned for chronic health points, where 2 is assigned “for elective postoperative subjects” and 5 is assigned “for nonoperative or emergency postoperative subjects”. For subjects who do not have a history of severe organ system insufficiency or who are not immunocompromised, a NOT DONE record may be retained from the source RS domain with the conditional branching flag (RSCBRFL="Y") populated. Additionally, a sponsor may choose to set AVAL=0 for subjects who do not meet the criteria for assigning chronic health points. This decision must be clearly documented, as the analysis value of 0 is logically derived or implied.

6     Example

6.1   Background

Analyses based on ADaM datasets may vary depending on the sponsor, therapeutic area, and the needs of regulatory authorities in their decision-making processes. This fictional example is provided for illustrative purposes only. The ADaM dataset describing the analysis results from an instrument is based on the protocol and statistical analysis plan (SAP) for the individual study.

The example dataset described here is intended to support a variety of analyses, ranging from simple univariate summary statistics on the actual total scores to other types of by-visit and repeated-measure analyses. For that reason, standard ADaM BDS variables such as AVAL (analysis value) have been included in the example. In addition, although not illustrated in the example, the APACHE II total score can be divided into categories (e.g., <17, >=17) reflecting disease severity or risk of death, and the frequency of subjects reporting in each category may be generated or used for analysis.

In the example presented here, it is assumed that the final APACHE II analysis dataset (ADAPCH) contains all of the original records, plus a record for the computed total acute physiology score and a record for the computed total APACHE II for each subject and assessment timepoint. The date of the assessment—and time of the assessment, if collected—should also be included in the dataset. For traceability, raw item-level responses from the SDTM RS.RSORRES variable, stored separately from the analysis variable AVAL, are included. Derivation type (DTYPE) should be used to clearly indicate records where missing values have been imputed using sponsor-defined imputation methods. If useful for analysis, a summary analysis dataset which includes only the computed total score records may also be created.

6.2   Example Analysis Dataset, Variable and Value-level Metadata

The ADAPCH Dataset Metadata table shows an example of how the APACHE II may be implemented in ADaM. The dataset metadata is a recommendation for the dataset name, label, structure, and keys. These can be modified for sponsor-specific standards and analyses. 

ADAPCH Dataset Metadata

The ADAPCH Variable Metadata table contains an example of analysis variable metadata for a subset of possible variables available for the APACHE II. Example value-level metadata are found in the Parameter Value List - ADAPCH metadata table. The ADAPCH Variable Metadata table does not include all of the possible variables that may be present in the Subject-Level Analysis Dataset (ADSL) and copied to the BDS structure analysis dataset, with the exception of the required STUDYID and USUBJID. For a complete list of available ADSL variables, consult the ADaMIG. Some ADSL variables (e.g., REGION1) were included in this example for stratification, and are not required. Additional covariates or other variables may be added as needed for analysis. Common BDS variables such as BASE and CHG have been omitted from the example as the majority analyses of APACHE II do not use these variables. There is no specific ordering of variables recommended in this supplement. The SDTM variables were placed next to the corresponding derived ADaM variables for illustration purposes only. 


ADAPCH Variable Metadata

The following SDTM variables can be copied into the corresponding equivalent ADaM variables. Note that the SDTM variable values can be converted to mixed case as needed for analysis purposes.  

SDTM Variable

ADaM Variable

RSTESTCD

PARAMCD

RSTEST

PARAM

RSCAT

PARCAT1

RSSTRESN

AVAL

All controlled terminology for instruments in both SDTM and ADaM is associated with a specific version of the instrument. When integrating responses from an instrument across studies, it is important to know which version of the instrument was used for each study. When multiple versions of the same instrument exist in an integration, a pooled analysis of responses across different versions can only be performed if determined to be clinically and statistically acceptable. In that case, sponsor-defined terminology, similar to CDISC Controlled Terminology but without the reference to a specific version, should be used for PARAMCD, PARAM and PARCATy.

Parameter Value List - ADAPCH

6.3   Example Analysis Dataset 

The APACHE II Analysis Dataset tables below show the terminology and variables for implementing the example analysis dataset for this instrument in the BDS. This specific example is taken from a Phase II, randomized, controlled, open label multi-center study to assess the efficacy and safety of Drug A for the treatment of SARS-CoV-2 infected subjects with COVID-19 pneumonia and impaired respiratory function. The primary outcome measure is APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (whichever is earlier). This measure compares "Drug A + SOC" with "SOC" (SOC = Standard of Care). 

In this example, the APACHE II was measured within 24 hours of ICU admission, on or before Day 1 (prior to implementation of treatment), Day 7, and Day 15 or on the day of discharge (whichever was earlier). In the example, as per the SAP, subjects who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the subjects at any time during the trial (worst case imputation for deaths). This imputation method is for example purposes only and not meant to be a recommendation nor considered a common practice. Missing data values for the parameters required for the derivation of the APACHE II score were replaced by the last available assessment. Item level imputation, in this example, is handled by the investigators and/or clinicians at the site and is considered source data, already captured in SDTM. SOC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

In the example, the SAP specifies that planned collected visits, including baseline measurements, are to be used in analyses and displays of results. In fact, no unscheduled visits exist in the source data. If the planned physiology assessment is not done or invalid, the investigator may choose to use a previous or repeat assessment of that parameter as the value at that visit for the scoring of APACHE II. The records for 2 subjects are shown in the example datasets. The data for 3 visits is shown for the first subject, with no missing data. The data for 1 visit is shown for the second subject, who died before the Day 15 (Day of Discharge) Visit so the APACHE II total score is imputed to the worst case value of any subjects across any timepoints at that visit. Note that the worst case value is not shown in the sample data.

APACHE II Complete Analysis Dataset

The APACHE II Complete Analysis Dataset table shows all of the individual item responses for this example, as well as the computed total Acute Physiology score and the computed total APACHE II score. This example is considered to be the final analysis dataset for submission. Computed total scores appear after the individual item responses, with appropriate labels for identification.

$titleHtml

adapch.xpt

RowSTUDYIDUSUBJIDSITEIDRSSEQASEQITTFLTRTPPARAMPARAMCDPARAMNPARCAT1VISITVISITNUMAVISITAVISITNRSDTCADTADYRSORRESRSORRESURSCBRFLAVALDTYPEABLFLCOUNTRYREGION1REGION1N
1STUDYXX-100-P000110011YDRUG A + SOCAPCH1-Temperature - RectalAPCH1011APACHE IISCREENING1Baseline02020-06-2929JUN2020138.5-38.9C
1

USANorth America1
2STUDYXX-100-P000110022YDRUG A + SOCAPCH1-Mean Arterial PressureAPCH1022APACHE IISCREENING1Baseline02020-06-2929JUN20201110-129mmHg
2

USANorth America1
3STUDYXX-100-P000110033YDRUG A + SOCAPCH1-Heart RateAPCH1033APACHE IISCREENING1Baseline02020-06-2929JUN2020170-109beats/min
0

USANorth America1
4STUDYXX-100-P000110044YDRUG A + SOCAPCH1-Respiratory RateAPCH1044APACHE IISCREENING1Baseline02020-06-2929JUN2020125-34breaths/min
1

USANorth America1
5STUDYXX-100-P000110055YDRUG A + SOCAPCH1-Oxygenation: A-aDO2APCH105A5APACHE IISCREENING1Baseline02020-06-2929JUN20201

Y


USANorth America1
6STUDYXX-100-P000110066YDRUG A + SOCAPCH1-Oxygenation: PaO2APCH105B6APACHE IISCREENING1Baseline02020-06-2929JUN2020161-70mmHg
1

USANorth America1
7STUDYXX-100-P000110077YDRUG A + SOCAPCH1-Arterial pHAPCH106A7APACHE IISCREENING1Baseline02020-06-2929JUN202017.15-7.24

3

USANorth America1
8STUDYXX-100-P000110088YDRUG A + SOCAPCH1-Serum HCO3APCH106B8APACHE IISCREENING1Baseline02020-06-2929JUN20201

Y


USANorth America1
9STUDYXX-100-P000110099YDRUG A + SOCAPCH1-Serum SodiumAPCH1079APACHE IISCREENING1Baseline02020-06-2929JUN20201150-154mmol/L
1

USANorth America1
10STUDYXX-100-P00011001010YDRUG A + SOCAPCH1-Serum PotassiumAPCH10810APACHE IISCREENING1Baseline02020-06-2929JUN202013.5-5.4mmol/L
0

USANorth America1
11STUDYXX-100-P00011001111YDRUG A + SOCAPCH1-Serum CreatinineAPCH10911APACHE IISCREENING1Baseline02020-06-2929JUN20201<0.6mg/dL
2

USANorth America1
12STUDYXX-100-P00011001212YDRUG A + SOCAPCH1-HematocritAPCH11012APACHE IISCREENING1Baseline02020-06-2929JUN2020120-29.9%
2

USANorth America1
13STUDYXX-100-P00011001313YDRUG A + SOCAPCH1-White Blood CountAPCH11113APACHE IISCREENING1Baseline02020-06-2929JUN2020120-39.910^9/L
2

USANorth America1
14STUDYXX-100-P00011001414YDRUG A + SOCAPCH1-15 Minus Glasgow Coma ScoreAPCH11214APACHE IISCREENING1Baseline02020-06-2929JUN202013

3

USANorth America1
15STUDYXX-100-P00011001515YDRUG A + SOCAPCH1-A: Total Acute Physiology ScoreAPCH11315APACHE IISCREENING1Baseline02020-06-2929JUN2020118

18

USANorth America1
16STUDYXX-100-P0001100
16YDRUG A + SOCAPCH1-A: Total Acute Physiology Score - AnalysisAPCH1TPS16APACHE IISCREENING1Baseline02020-06-2929JUN20201


18
YUSANorth America1
17STUDYXX-100-P00011001617YDRUG A + SOCAPCH1-B: Age PointsAPCH11417APACHE IISCREENING1Baseline02020-06-2929JUN2020145-54YEARS
2

USANorth America1
18STUDYXX-100-P00011001718YDRUG A + SOCAPCH1-C: Chronic Health PointsAPCH11518APACHE IISCREENING1Baseline02020-06-2929JUN20201for elective postoperative patients

2

USANorth America1
19STUDYXX-100-P00011001819YDRUG A + SOCAPCH1-Total APACHE II ScoreAPCH11619APACHE IISCREENING1Baseline02020-06-2929JUN2020122

22

USANorth America1
20STUDYXX-100-P0001100
20YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IISCREENING1Baseline02020-06-2929JUN20201


22
YUSANorth America1
21STUDYXX-100-P00011001921YDRUG A + SOCAPCH1-Temperature - RectalAPCH1011APACHE IIDAY 77Day 772020-07-0505JUL2020738.5-38.9C
1

USANorth America1
22STUDYXX-100-P00011002022YDRUG A + SOCAPCH1-Mean Arterial PressureAPCH1022APACHE IIDAY 77Day 772020-07-0505JUL2020770–109mmHg
0

USANorth America1
23STUDYXX-100-P00011002123YDRUG A + SOCAPCH1-Heart RateAPCH1033APACHE IIDAY 77Day 772020-07-0505JUL2020770-109beats/min
0

USANorth America1
24STUDYXX-100-P00011002224YDRUG A + SOCAPCH1-Respiratory RateAPCH1044APACHE IIDAY 77Day 772020-07-0505JUL2020725-34breaths/min
1

USANorth America1
25STUDYXX-100-P00011002325YDRUG A + SOCAPCH1-Oxygenation: A-aDO2APCH105A5APACHE IIDAY 77Day 772020-07-0505JUL20207

Y


USANorth America1
26STUDYXX-100-P00011002426YDRUG A + SOCAPCH1-Oxygenation: PaO2APCH105B6APACHE IIDAY 77Day 772020-07-0505JUL2020761-70mmHg
1

USANorth America1
27STUDYXX-100-P00011002527YDRUG A + SOCAPCH1-Arterial pHAPCH106A7APACHE IIDAY 77Day 772020-07-0505JUL202077.25-7.32

2

USANorth America1
28STUDYXX-100-P00011002628YDRUG A + SOCAPCH1-Serum HCO3APCH106B8APACHE IIDAY 77Day 772020-07-0505JUL20207

Y


USANorth America1
29STUDYXX-100-P00011002729YDRUG A + SOCAPCH1-Serum SodiumAPCH1079APACHE IIDAY 77Day 772020-07-0505JUL20207150-154mmol/L
1

USANorth America1
30STUDYXX-100-P00011002830YDRUG A + SOCAPCH1-Serum PotassiumAPCH10810APACHE IIDAY 77Day 772020-07-0505JUL202073.5-5.4mmol/L
0

USANorth America1
31STUDYXX-100-P00011002931YDRUG A + SOCAPCH1-Serum CreatinineAPCH10911APACHE IIDAY 77Day 772020-07-0505JUL202070.6-1.4mg/dL
0

USANorth America1
32STUDYXX-100-P00011003032YDRUG A + SOCAPCH1-HematocritAPCH11012APACHE IIDAY 77Day 772020-07-0505JUL2020720-29.9%
2

USANorth America1
33STUDYXX-100-P00011003133YDRUG A + SOCAPCH1-White Blood CountAPCH11113APACHE IIDAY 77Day 772020-07-0505JUL2020715-19.910^9/L
1

USANorth America1
34STUDYXX-100-P00011003234YDRUG A + SOCAPCH1-15 Minus Glasgow Coma ScoreAPCH11214APACHE IIDAY 77Day 772020-07-0505JUL202071

1

USANorth America1
35STUDYXX-100-P00011003335YDRUG A + SOCAPCH1-A: Total Acute Physiology ScoreAPCH11315APACHE IIDAY 77Day 772020-07-0505JUL2020710

10

USANorth America1
36STUDYXX-100-P0001100
36YDRUG A + SOCAPCH1-A: Total Acute Physiology Score - AnalysisAPCH1TPS16APACHE IIDAY 77Day 772020-07-0505JUL20207


10

USANorth America1
37STUDYXX-100-P00011003437YDRUG A + SOCAPCH1-B: Age PointsAPCH11417APACHE IIDAY 77Day 772020-07-0505JUL2020745-54YEARS
2

USANorth America1
38STUDYXX-100-P00011003538YDRUG A + SOCAPCH1-C: Chronic Health PointsAPCH11518APACHE IIDAY 77Day 772020-07-0505JUL20207for elective postoperative patients

2

USANorth America1
39STUDYXX-100-P00011003639YDRUG A + SOCAPCH1-Total APACHE II ScoreAPCH11619APACHE IIDAY 77Day 772020-07-0505JUL2020714

14

USANorth America1
40STUDYXX-100-P0001100
40YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IIDAY 77Day 772020-07-0505JUL20207


14

USANorth America1
41STUDYXX-100-P00011003741YDRUG A + SOCAPCH1-Temperature - RectalAPCH1011APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201536-38.4C
0

USANorth America1
42STUDYXX-100-P00011003842YDRUG A + SOCAPCH1-Mean Arterial PressureAPCH1022APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201570–109mmHg
0

USANorth America1
43STUDYXX-100-P00011003943YDRUG A + SOCAPCH1-Heart RateAPCH1033APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201570-109beats/min
0

USANorth America1
44STUDYXX-100-P00011004044YDRUG A + SOCAPCH1-Respiratory RateAPCH1044APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201512–24breaths/min
0

USANorth America1
45STUDYXX-100-P00011004145YDRUG A + SOCAPCH1-Oxygenation: A-aDO2APCH105A5APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015

Y


USANorth America1
46STUDYXX-100-P00011004246YDRUG A + SOCAPCH1-Oxygenation: PaO2APCH105B6APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201561-70mmHg
1

USANorth America1
47STUDYXX-100-P00011004347YDRUG A + SOCAPCH1-Arterial pHAPCH106A7APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020157.33-7.49

0

USANorth America1
48STUDYXX-100-P00011004448YDRUG A + SOCAPCH1-Serum HCO3APCH106B8APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015

Y


USANorth America1
49STUDYXX-100-P00011004549YDRUG A + SOCAPCH1-Serum SodiumAPCH1079APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015130-149mmol/L
0

USANorth America1
50STUDYXX-100-P00011004650YDRUG A + SOCAPCH1-Serum PotassiumAPCH10810APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020153.5-5.4mmol/L
0

USANorth America1
51STUDYXX-100-P00011004751YDRUG A + SOCAPCH1-Serum CreatinineAPCH10911APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020150.6-1.4mg/dL
0

USANorth America1
52STUDYXX-100-P00011004852YDRUG A + SOCAPCH1-HematocritAPCH11012APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201546-49.9%
1

USANorth America1
53STUDYXX-100-P00011004953YDRUG A + SOCAPCH1-White Blood CountAPCH11113APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020153-14.910^9/L
0

USANorth America1
54STUDYXX-100-P00011005054YDRUG A + SOCAPCH1-15 Minus Glasgow Coma ScoreAPCH11214APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020150

0

USANorth America1
55STUDYXX-100-P00011005155YDRUG A + SOCAPCH1-A: Total Acute Physiology ScoreAPCH11315APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020152

2

USANorth America1
56STUDYXX-100-P0001100
56YDRUG A + SOCAPCH1-A: Total Acute Physiology Score - AnalysisAPCH1TPS16APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015


2

USANorth America1
57STUDYXX-100-P00011005257YDRUG A + SOCAPCH1-B: Age PointsAPCH11417APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL20201545-54YEARS
2

USANorth America1
58STUDYXX-100-P00011005358YDRUG A + SOCAPCH1-C: Chronic Health PointsAPCH11518APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015for elective postoperative patients

2

USANorth America1
59STUDYXX-100-P00011005459YDRUG A + SOCAPCH1-Total APACHE II ScoreAPCH11619APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL2020156

6

USANorth America1
60STUDYXX-100-P0001100
60YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IIDAY 1515Day 15 (Day of Discharge)152020-07-1313JUL202015


6

USANorth America1
61STUDYXX-200-P000220011YSOCAPCH1-Temperature - RectalAPCH1011APACHE IISCREENING1Baseline02020-08-0404AUG2020-138.5-38.9C
1

GBRNon-North America0
62STUDYXX-200-P000220022YSOCAPCH1-Mean Arterial PressureAPCH1022APACHE IISCREENING1Baseline02020-08-0404AUG2020-1110-129mmHg
2

GBRNon-North America0
63STUDYXX-200-P000220033YSOCAPCH1-Heart RateAPCH1033APACHE IISCREENING1Baseline02020-08-0404AUG2020-170-109beats/min
0

GBRNon-North America0
64STUDYXX-200-P000220044YSOCAPCH1-Respiratory RateAPCH1044APACHE IISCREENING1Baseline02020-08-0404AUG2020-1>=50breaths/min
4

GBRNon-North America0
65STUDYXX-200-P000220055YSOCAPCH1-Oxygenation: A-aDO2APCH105A5APACHE IISCREENING1Baseline02020-08-0404AUG2020-1

Y


GBRNon-North America0
66STUDYXX-200-P000220066YSOCAPCH1-Oxygenation: PaO2APCH105B6APACHE IISCREENING1Baseline02020-08-0404AUG2020-161-70mmHg
1

GBRNon-North America0
67STUDYXX-200-P000220077YSOCAPCH1-Arterial pHAPCH106A7APACHE IISCREENING1Baseline02020-08-0404AUG2020-1<7.15

4

GBRNon-North America0
68STUDYXX-200-P000220088YSOCAPCH1-Serum HCO3APCH106B8APACHE IISCREENING1Baseline02020-08-0404AUG2020-1

Y


GBRNon-North America0
69STUDYXX-200-P000220099YSOCAPCH1-Serum SodiumAPCH1079APACHE IISCREENING1Baseline02020-08-0404AUG2020-1150-154mmol/L
1

GBRNon-North America0
70STUDYXX-200-P00022001010YSOCAPCH1-Serum PotassiumAPCH10810APACHE IISCREENING1Baseline02020-08-0404AUG2020-13.5-5.4mmol/L
0

GBRNon-North America0
71STUDYXX-200-P00022001111YSOCAPCH1-Serum CreatinineAPCH10911APACHE IISCREENING1Baseline02020-08-0404AUG2020-1<0.6mg/dL
2

GBRNon-North America0
72STUDYXX-200-P00022001212YSOCAPCH1-HematocritAPCH11012APACHE IISCREENING1Baseline02020-08-0404AUG2020-120-29.9%
2

GBRNon-North America0
73STUDYXX-200-P00022001313YSOCAPCH1-White Blood CountAPCH11113APACHE IISCREENING1Baseline02020-08-0404AUG2020-1>=4010^9/L
4

GBRNon-North America0
74STUDYXX-200-P00022001414YSOCAPCH1-15 Minus Glasgow Coma ScoreAPCH11214APACHE IISCREENING1Baseline02020-08-0404AUG2020-13

3

GBRNon-North America0
75STUDYXX-200-P00022001515YSOCAPCH1-A: Total Acute Physiology ScoreAPCH11315APACHE IISCREENING1Baseline02020-08-0404AUG2020-124

24

GBRNon-North America0
76STUDYXX-200-P0002200
16YSOCAPCH1-A: Total Acute Physiology Score - AnalysisAPCH1TPS16APACHE IISCREENING1Baseline02020-08-0404AUG2020-1


24
YGBRNon-North America0
77STUDYXX-200-P00022001617YSOCAPCH1-B: Age PointsAPCH11417APACHE IISCREENING1Baseline02020-08-0404AUG2020-165-74YEARS
5

GBRNon-North America0
78STUDYXX-200-P00022001718YSOCAPCH1-C: Chronic Health PointsAPCH11518APACHE IISCREENING1Baseline02020-08-0404AUG2020-1for elective postoperative patients

2

GBRNon-North America0
79STUDYXX-200-P00022001819YSOCAPCH1-Total APACHE II ScoreAPCH11619APACHE IISCREENING1Baseline02020-08-0404AUG2020-131

31

GBRNon-North America0
80STUDYXX-200-P0002200
20YSOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IISCREENING1Baseline02020-08-0404AUG2020-1


31
YGBRNon-North America0
81STUDYXX-200-P0002200
21YSOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE II

Day 15 (Day of Discharge)15
09AUG20205


38WOC
GBRNon-North America0
$warningHtml
APACHE II Summary Analysis Dataset

Due to the number of items on the instrument and the fact that only the total APACHE II score records are required for analysis, the separate summary dataset shown in the following example, which contains only the total APACHE II score records, may also be created.  RSSEQ was not included in this example because it would be null for all computed total score records. RSORRES is not shown because only derived total score records are displayed.

$titleHtml

adapchs.xpt

RowSTUDYIDUSUBJIDSITEIDASEQITTFLTRTPPARAMPARAMCDPARAMNPARCAT1VISITVISITNUMAVISITAVISITNADTADYAVALDTYPEABLFLCOUNTRYREGION1REGION1N
20STUDYXX-100-P000110020YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IISCREENING1Baseline029JUN2020122
YUSANorth America1
40STUDYXX-100-P000110040YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IIDAY 77Day 7705JUL2020714

USANorth America1
60STUDYXX-100-P000110060YDRUG A + SOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IIDAY 1515Day 15 (Day of Discharge)1513JUL2020156

USANorth America1
80STUDYXX-200-P000220020YSOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE IISCREENING1Baseline004AUG2020-131
YGBRNon-North America0
81STUDYXX-200-P000220021YSOCAPCH1-Total APACHE II Score - AnalysisAPCH1TS20APACHE II

Day 15 (Day of Discharge)1509AUG2020538WOC
GBRNon-North America

0

$warningHtml

7   References

  1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985; 13(10):818–29. 

End of Document




  • No labels